Glucose-Induced β-Catenin Acetylation Enhances Wnt Signaling in Cancer

Molecular Cell

Volumn 49, Issue 3, 2013, Pages 474-486

  Chocarro Calvo, Ana ^a   García Martínez, Jose Manuel ^a   Ardila González, Soraya ^a   De la Vieja, Antonio ^b   García Jiménez, Custodia ^a  

^a UNIVERSIDAD REY JUAN CARLOS   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

BETA CATENIN; E1A ASSOCIATED P300 PROTEIN; GLUCOSE; LYSINE; SIRTUIN; WNT PROTEIN;

ACETYLATION; ARTICLE; CELL STIMULATION; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE ASSOCIATION; FEMALE; HUMAN; HUMAN CELL; MOLECULAR MECHANICS; NEOPLASM; NUCLEAR LOCALIZATION SIGNAL; OBESITY; SIGNAL TRANSDUCTION; STIMULUS;

ACETYLATION; BETA CATENIN; CELL LINE, TUMOR; CELL NUCLEUS; CHROMATIN; CYTOSOL; E1A-ASSOCIATED P300 PROTEIN; GASTRIC INHIBITORY POLYPEPTIDE; GLUCOSE; HUMANS; LITHIUM CHLORIDE; LYMPHOID ENHANCER-BINDING FACTOR 1; NEOPLASMS; PROMOTER REGIONS, GENETIC; PROTEIN BINDING; PROTEIN STABILITY; SIRTUINS; TCF TRANSCRIPTION FACTORS; TRANSCRIPTION, GENETIC; TRANSCRIPTIONAL ACTIVATION; WNT SIGNALING PATHWAY; WNT3A PROTEIN;

EID: 84873415451     PISSN: 10972765     EISSN: 10974164     Source Type: Journal    
DOI: 10.1016/j.molcel.2012.11.022     Document Type: Article

References (46)

1. Anagnostou S.H., Shepherd P.R. Glucose induces an autocrine activation of the Wnt/beta-catenin pathway in macrophage cell lines. Biochem. J. 2008, 416:211-218.
2. Andrews N.C., Faller D.V. A rapid micropreparation technique for extraction of DNA-binding proteins from limiting numbers of mammalian cells. Nucleic Acids Res. 1991, 19:2499.
3. Audrito V., Vaisitti T., Rossi D., Gottardi D., D'Arena G., Laurenti L., Gaidano G., Malavasi F., Deaglio S. Nicotinamide blocks proliferation and induces apoptosis of chronic lymphocytic leukemia cells through activation of the p53/miR-34a/SIRT1 tumor suppressor network. Cancer Res. 2011, 71:4473-4483.
4. Bafico A., Liu G., Goldin L., Harris V., Aaronson S.A. An autocrine mechanism for constitutive Wnt pathway activation in human cancer cells. Cancer Cell 2004, 6:497-506.
5. Barker N., Ridgway R.A., van Es J.H., van de Wetering M., Begthel H., van den Born M., Danenberg E., Clarke A.R., Sansom O.J., Clevers H. Crypt stem cells as the cells-of-origin of intestinal cancer. Nature 2009, 457:608-611.
6. Clevers H. Wnt/beta-catenin signaling in development and disease. Cell 2006, 127:469-480.
7. Delmas V., Beermann F., Martinozzi S., Carreira S., Ackermann J., Kumasaka M., Denat L., Goodall J., Luciani F., Viros A., et al. Beta-catenin induces immortalization of melanocytes by suppressing p16INK4a expression and cooperates with N-Ras in melanoma development. Genes Dev. 2007, 21:2923-2935.
8. Dowling R.J., Zakikhani M., Fantus I.G., Pollak M., Sonenberg N. Metformin inhibits mammalian target of rapamycin-dependent translation initiation in breast cancer cells. Cancer Res. 2007, 67:10804-10812.
9. Efeyan A., Sabatini D.M. mTOR and cancer: many loops in one pathway. Curr. Opin. Cell Biol. 2010, 22:169-176.
10. Firestein R., Blander G., Michan S., Oberdoerffer P., Ogino S., Campbell J., Bhimavarapu A., Luikenhuis S., de Cabo R., Fuchs C., et al. The SIRT1 deacetylase suppresses intestinal tumorigenesis and colon cancer growth. PLoS ONE 2008, 3:e2020.
11. Flatt P.R., Green B.D. Nutrient regulation of pancreatic beta-cell function in diabetes: problems and potential solutions. Biochem. Soc. Trans. 2006, 34:774-778.
12. Gao C., Yao S.K. Diabetes mellitus: a " true" independent risk factor for hepatocellular carcinoma?. HBPD INT 2009, 8:465-473.
13. García-Jiménez C. Wnt and incretin connections. Vitam. Horm. 2010, 84:355-387.
14. García-Martínez J.M., Chocarro-Calvo A., Moya C.M., García-Jiménez C. WNT/beta-catenin increases the production of incretins by entero-endocrine cells. Diabetologia 2009, 52:1913-1924.
15. Gerber M. Background review paper on total fat, fatty acid intake and cancers. Ann. Nutr. Metab. 2009, 55:140-161.
16. Giovannucci E., Harlan D.M., Archer M.C., Bergenstal R.M., Gapstur S.M., Habel L.A., Pollak M., Regensteiner J.G., Yee D. Diabetes and cancer: a consensus report. Diabetes Care 2010, 33:1674-1685.
17. Gnagnarella P., Gandini S., La Vecchia C., Maisonneuve P. Glycemic index, glycemic load, and cancer risk: a meta-analysis. Am. J. Clin. Nutr. 2008, 87:1793-1801.
18. Gualberto A., Pollak M. Emerging role of insulin-like growth factor receptor inhibitors in oncology: early clinical trial results and future directions. Oncogene 2009, 28:3009-3021.
19. Hecht A., Vleminckx K., Stemmler M.P., van Roy F., Kemler R. The p300/CBP acetyltransferases function as transcriptional coactivators of beta-catenin in vertebrates. EMBO J. 2000, 19:1839-1850.
20. Hillon P., Guiu B., Vincent J., Petit J.M. Obesity, type 2 diabetes and risk of digestive cancer. Gastroenterol. Clin. Biol. 2010, 34:529-533.
21. Huber O., Korn R., McLaughlin J., Ohsugi M., Herrmann B.G., Kemler R. Nuclear localization of beta-catenin by interaction with transcription factor LEF-1. Mech. Dev. 1996, 59:3-10.
22. Khandekar M.J., Cohen P., Spiegelman B.M. Molecular mechanisms of cancer development in obesity. Nat. Rev. Cancer 2011, 11:886-895.
23. Kim K., Hay E.D. New evidence that nuclear import of endogenous beta-catenin is LEF-1 dependent, while LEF-1 independent import of exogenous beta-catenin leads to nuclear abnormalities. Cell Biol. Int. 2001, 25:1149-1161.
24. Kinzler K.W., Vogelstein B. Lessons from hereditary colorectal cancer. Cell 1996, 87:159-170.
25. Korinek V., Barker N., Willert K., Molenaar M., Roose J., Wagenaar G., Markman M., Lamers W., Destree O., Clevers H. Two members of the Tcf family implicated in Wnt/beta-catenin signaling during embryogenesis in the mouse. Mol. Cell. Biol. 1998, 18:1248-1256.
26. Lévy L., Wei Y., Labalette C., Wu Y., Renard C.A., Buendia M.A., Neuveut C. Acetylation of beta-catenin by p300 regulates beta-catenin-Tcf4 interaction. Mol. Cell. Biol. 2004, 24:3404-3414.
27. Liu Z., Habener J.F. Glucagon-like peptide-1 activation of TCF7L2-dependent Wnt signaling enhances pancreatic beta cell proliferation. J. Biol. Chem. 2008, 283:8723-8735.
28. Livak K.J., Schmittgen T.D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 2001, 25:402-408.
29. Lyssenko V. The transcription factor 7-like 2 gene and increased risk of type 2 diabetes: an update. Curr. Opin. Clin. Nutr. Metab. Care 2008, 11:385-392.
30. Ma H., Nguyen C., Lee K.S., Kahn M. Differential roles for the coactivators CBP and p300 on TCF/beta-catenin-mediated survivin gene expression. Oncogene 2005, 24:3619-3631.
31. McIntosh C.H., Widenmaier S., Kim S.J. Glucose-dependent insulinotropic polypeptide (Gastric Inhibitory Polypeptide; GIP). Vitam. Horm. 2009, 80:409-471.
32. Morton J.P., Myant K.B., Sansom O.J. A FAK-PI-3K-mTOR axis is required for Wnt-Myc driven intestinal regeneration and tumorigenesis. Cell Cycle 2011, 10:173-175.
33. Nauck M.A., Bartels E., Orskov C., Ebert R., Creutzfeldt W. Additive insulinotropic effects of exogenous synthetic human gastric inhibitory polypeptide and glucagon-like peptide-1-(7-36) amide infused at near-physiological insulinotropic hormone and glucose concentrations. J. Clin. Endocrinol. Metab. 1993, 76:912-917.
34. Orsulic S., Peifer M. An in vivo structure-function study of armadillo, the beta-catenin homologue, reveals both separate and overlapping regions of the protein required for cell adhesion and for wingless signaling. J. Cell Biol. 1996, 134:1283-1300.
35. Pisani P. Hyper-insulinaemia and cancer, meta-analyses of epidemiological studies. Arch. Physiol. Biochem. 2008, 114:63-70.
36. Prieve M.G., Waterman M.L. Nuclear localization and formation of beta-catenin-lymphoid enhancer factor 1 complexes are not sufficient for activation of gene expression. Mol. Cell. Biol. 1999, 19:4503-4515.
37. Renehan A.G., Tyson M., Egger M., Heller R.F., Zwahlen M. Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet 2008, 371:569-578.
38. Sauve A.A., Schramm V.L. Sir2 regulation by nicotinamide results from switching between base exchange and deacetylation chemistry. Biochemistry 2003, 42:9249-9256.
39. Saxena R., Gianniny L., Burtt N.P., Lyssenko V., Giuducci C., Sjögren M., Florez J.C., Almgren P., Isomaa B., Orho-Melander M., et al. Common single nucleotide polymorphisms in TCF7L2 are reproducibly associated with type 2 diabetes and reduce the insulin response to glucose in nondiabetic individuals. Diabetes 2006, 55:2890-2895.
40. Tennant D.A., Durán R.V., Gottlieb E. Targeting metabolic transformation for cancer therapy. Nat. Rev. Cancer 2010, 10:267-277.
41. Vigneri R. Diabetes: diabetes therapy and cancer risk. Nat. Rev. Endocrinol. 2009, 5:651-652.
42. von Kries J.P., Winbeck G., Asbrand C., Schwarz-Romond T., Sochnikova N., Dell'Oro A., Behrens J., Birchmeier W. Hot spots in beta-catenin for interactions with LEF-1, conductin and APC. Nat. Struct. Biol. 2000, 7:800-807.
43. Warburg O., Geissler A.W., Lorenz S. [On growth of cancer cells in media in which glucose is replaced by galactose]. Hoppe Seylers Z. Physiol. Chem. 1967, 348:1686-1687.
44. Wolf D., Rodova M., Miska E.A., Calvet J.P., Kouzarides T. Acetylation of beta-catenin by CREB-binding protein (CBP). J. Biol. Chem. 2002, 277:25562-25567.
45. Wu D., Pan W. GSK3: a multifaceted kinase in Wnt signaling. Trends Biochem. Sci. 2010, 35:161-168.
46. Xu W., Kimelman D. Mechanistic insights from structural studies of beta-catenin and its binding partners. J. Cell Sci. 2007, 120:3337-3344.